Kirby Institute modelling could assist pandemic exit strategy


Thursday, 13 May, 2021


Kirby Institute modelling could assist pandemic exit strategy

UNSW’s Kirby Institute has used mathematical modelling to test the effectiveness of different vaccination strategies for controlling the COVID-19 pandemic, comparing scenarios of limited vaccine supply against mass vaccination.

A targeted vaccine strategy will be critical in preventing infections and reducing deaths if supply does not allow for mass vaccination.

Published in the journal Vaccine, the research used the population of NSW as a case study for a hypothetical epidemic scenario starting with 100 cases per day. It provides a roadmap for vaccination goals and possible outcomes of vaccine programs during an epidemic.

The researchers determined that mass vaccination — in this case, vaccinating 66% of the population — with a vaccine efficacy of at least 70% against all infection (both symptomatic and asymptomatic) could achieve herd immunity, and represents the best exit strategy from the pandemic. In NSW, with a population of 7.5 million people, this would mean distributing 60,000–125,000 doses per day, based on the epidemic scenario.

But as Australia’s vaccine supply has, to date, been limited, there has been a necessary recalibration of the vaccination program to adopt a more targeted approach.

“A limited supply requires a targeted strategy where particular populations are prioritised,” explained study lead Professor Raina MacIntyre. “We show that for a population of 7.5 million people, if faced with an epidemic and an initial restriction in vaccine supply, sustained epidemic control cannot be achieved by this smaller, targeted vaccination strategy. Other non-pharmaceutical interventions, such as face mask use, physical distancing and limits on the movement of people through travel, will need to continue to mitigate any outbreaks.”

As part of this targeted approach, health worker vaccination is a top priority and is required for health system resilience. More vulnerable Australians, such as people who are immunocompromised and the elderly, are also prioritised. This approach has the benefit of bolstering essential health system infrastructure and reducing the number of deaths from serious COVID-19 disease, but does not have an impact on epidemic control.

Vaccines as post-exposure prophylaxis

With limited supply, the study examined the concept of using vaccines as post-exposure prophylaxis (PEP), meaning people could be vaccinated following exposure to a close contact who tested positive for COVID-19, preventing them from contracting the disease.

“Vaccines are effective as post-exposure prophylaxis for other infections, such as smallpox, hepatitis A and measles, but we’re yet to test whether COVID-19 vaccines would work in the same way,” Professor MacIntyre said.

Researchers in NSW are starting to study vaccine as PEP for SARS-CoV-2, and are hopeful that it will work, as this strategy tends to be successful for viruses with a longer incubation period, which SARS-CoV-2 has.

“The study provides a rationale for testing the use of vaccines in close contacts of COVID-19 and, if the vaccine proves to be effective when used as PEP, this would be the best use of a limited supply,” Professor MacIntyre said.

The optimal vaccine approach

The ideal approach is mass vaccination, which involves vaccinating an entire population to achieve herd immunity. This approach requires adequate vaccine supply, and has not been undertaken anywhere in the world since the eradication of smallpox.

“Mass vaccination is a huge undertaking, requiring an enormous amount of resources, from workforce and infrastructure to a smooth flow of vaccine supply,” Professor MacIntyre said.

The model demonstrates that rapid vaccination is critical. The efficacy of vaccines, coupled with the capacity to deliver them, impacts on the level of pandemic control and the speed at which herd immunity can potentially be achieved.

“The Pfizer vaccine, which is one of the two vaccines currently available in Australia, has been shown to be 92% effective against all infection, so could potentially achieve herd immunity,” Professor MacIntyre said. “Trial data on the AstraZeneca vaccine shows it does not prevent asymptomatic infection as well, so whether this vaccine can achieve herd immunity is unknown as yet. We do not know yet if boosters will be needed, but high efficacy is the first step toward herd immunity.”

The study shows that ultimately, adequate and effective vaccine supply coupled with rapid delivery is the only way to prevent sustained transmission in the community, and improve prospects for economic recovery by removing the need for ongoing social restrictions.

“While our model shows that a targeted vaccine strategy can still reduce illness and death from COVID-19, it is clear that a mass vaccination strategy would be far more effective at controlling disease,” Professor MacIntyre said. “Encouragingly, our model suggests that herd immunity can be achieved in states like NSW by vaccinating two-thirds of the population with a high-efficacy vaccine.”

Image credit: ©stock.adobe.com/au/oxinoxi

Related News

Flinders University joins male health research alliance

Flinders University has become a research partner of the Freemasons Centre for Male Health &...

Fish oil's role in stopping superbugs

Australian scientists have discovered that regular fish oil has the potential to break down...

PanKind initiative sets sights on early detection of pancreatic cancer

PanKind has launched the PanKind Early Detection Initiative in a move to strategically work with...


  • All content Copyright © 2021 Westwick-Farrow Pty Ltd